{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["England BR"],"funding":["BLRD VA","RRD VA","HSRD VA","NIAMS NIH HHS","NIGMS NIH HHS","CSRD VA"],"pagination":["e166-e177"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12337451"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(3)"],"pubmed_abstract":["<h4>Background</h4>Uncertainty exists regarding patient outcomes when using TNF inhibitors versus other biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis-associated interstitial lung disease (ILD). We compared survival and respiratory hospitalisation outcomes following initiation of TNF-inhibitor or non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD.<h4>Methods</h4>We did a retrospective, active-comparator, new-user, observational cohort study with propensity score matching following the target trial emulation framework using US Department of Veterans Affairs (VA) electronic and administrative health records. VA health-care enrollees with rheumatoid arthritis-associated ILD an"],"journal":["The Lancet. Rheumatology"],"pubmed_title":["Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study."],"pmcid":["PMC12337451"],"funding_grant_id":["I01 RX003644","P30 AR072583","I01 BX004660","P20 GM130423","I01 CX001703","SDR 02-237","U54 GM115458","IK2 CX002203"],"pubmed_authors":["Frideres H","Roul P","Rojas J","Sauer BC","Baker JF","England BR","Johnson TM","Yu F","Mikuls TR","Curtis JR","Sayles H","Matson SM","Yang Y","George MD","Cannon GW"],"additional_accession":[]},"is_claimable":false,"name":"Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study.","description":"<h4>Background</h4>Uncertainty exists regarding patient outcomes when using TNF inhibitors versus other biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis-associated interstitial lung disease (ILD). We compared survival and respiratory hospitalisation outcomes following initiation of TNF-inhibitor or non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD.<h4>Methods</h4>We did a retrospective, active-comparator, new-user, observational cohort study with propensity score matching following the target trial emulation framework using US Department of Veterans Affairs (VA) electronic and administrative health records. VA health-care enrollees with rheumatoid arthritis-associated ILD an","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-06T10:55:20.834Z","creation":"2026-05-29T03:12:47.654Z"},"accession":"S-EPMC12337451","cross_references":{"pubmed":["39793598"],"doi":["10.1016/s2665-9913(24)00265-0","10.1016/S2665-9913(24)00265-0"]}}